ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors

ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors

[1]  P. Major,et al.  Effect of bisphosphonates on pain and quality of life in patients with bone metastases , 2009, Nature Clinical Practice Oncology.

[2]  D. Le Guludec,et al.  Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Atul C Mehta,et al.  Diagnosis of lung cancer: the guidelines. , 2003, Chest.

[4]  J. Reubi.  Somatostatin and Other Peptide Receptors as Tools for Tumor Diagnosis and Treatment , 2004, Neuroendocrinology.

[5]  M. Mignon.  Natural History of Neuroendocrine Enteropancreatic Tumors , 2000, Digestion.

[6]  M. Krzakowski,et al.  [Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors)]. , 2008, Endokrynologia Polska.

[7]  B. Eriksson,et al.  Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. , 2005, Best practice & research. Clinical endocrinology & metabolism.

[8]  H. Boot,et al.  Evaluation of 111In-pentetreotide, 131I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease , 2002, Nuclear medicine communications.

[9]  B. Taal,et al.  Metastatic carcinoid tumors: a clinical review. , 2005, The oncologist.

[10]  E. Chow,et al.  Validation of symptom clusters in patients with metastatic bone pain , 2008, Current oncology.

[11]  M. Falconi,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Tumour/Carcinoma of the Appendix and Goblet Cell Carcinoma , 2007, Neuroendocrinology.

[12]  Raymond Sawaya,et al.  Carcinoid metastasis to the brain , 2004, Cancer.

[13]  O. Clark,et al.  Pulmonary metastases of endocrine origin: the role of surgery. , 1998, Chest.

[14]  R. Jensen,et al.  Well-Differentiated Duodenal Tumor/Carcinoma (Excluding Gastrinomas) , 2007, Neuroendocrinology.

[15]  W. Cacheux,et al.  Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France , 2008, Neuroendocrinology.

[16]  B. Kos-Kudła,et al.  Well-Differentiated Gastric Tumors/Carcinomas , 2007, Neuroendocrinology.

[17]  E. D. de Vries,et al.  Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[19]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[20]  R. Jensen,et al.  Gastrinoma (Duodenal and Pancreatic) , 2007, Neuroendocrinology.

[21]  A. Scarpa,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours : Well-Differentiated Colon and Rectum Tumour / Carcinoma , 2007 .

[22]  L. Holmberg,et al.  Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  J. Miller,et al.  The surgical spectrum of pulmonary neuroendocrine neoplasms. , 2001, Chest.

[24]  A. Scarpa,et al.  Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary , 2007, Neuroendocrinology.

[25]  T. Meyer,et al.  Parathyroid Hormone-Related Peptide-Secreting Pancreatic Neuroendocrine Tumours: Case Series and Literature Review , 2008, Neuroendocrinology.

[26]  R. Lebtahi,et al.  Imaging appearances of metastases from neuroendocrine tumours of the pancreas. , 2001, The British journal of radiology.

[27]  M. Kulke,et al.  Emerging therapies for the treatment of patients with advanced neuroendocrine tumors , 2007, Expert opinion on emerging drugs.

[28]  O. Visser,et al.  Epidemiology of Neuroendocrine Tumours , 2004, Neuroendocrinology.

[29]  M. Korbonits,et al.  Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. , 2008, Endocrine-related cancer.

[30]  R. Felix,et al.  Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours , 2005, European Radiology.

[31]  M. Coleman,et al.  Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. , 2007, Gastroenterology.

[32]  A. Fairchild,et al.  Role of radiation therapy and radiopharmaceuticals in bone metastases , 2007, Current opinion in supportive and palliative care.

[33]  L. Kvols,et al.  Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma , 2007, Neuroendocrinology.

[34]  B. Kos-Kudła,et al.  Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin , 2007, Neuroendocrinology.

[35]  A. Grossman,et al.  The diagnosis and medical management of advanced neuroendocrine tumors. , 2004, Endocrine reviews.

[36]  F. Gleeson,et al.  Anatomic and functional imaging of metastatic carcinoid tumors. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[37]  W. Roberts,et al.  The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. , 1985, The American journal of medicine.

[38]  M. Falconi,et al.  Rare Functioning Pancreatic Endocrine Tumors , 2006, Neuroendocrinology.

[39]  B. Wiedenmann,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma , 2007, Neuroendocrinology.

[40]  F. Keleştimur,et al.  Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic) , 2007, Neuroendocrinology.

[41]  Irvin M Modlin,et al.  Bronchopulmonary neuroendocrine tumors , 2008, Cancer.

[42]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  E. Krenning,et al.  Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours , 2005 .

[44]  I. Gkialas,et al.  The use of radioisotopes for palliation of metastatic bone pain. , 2008, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[45]  M. Falconi,et al.  Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma , 2007, Neuroendocrinology.

[46]  M. Chung,et al.  Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[47]  A. Groves,et al.  Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG , 2008, Cancer.